CAR T Cell Therapy | CHOP Research Institute

Cell and Gene Therapy Stories Lead Our Most Popular of 2023

Published on

Dec 28, 2023

These six stories received the highest number of engagements on CHOP Research social media channels in 2023.

BEAM-201

The purpose of this study is to determine the safety and effectiveness of an experimental form of therapy, known as BEAM-201.

UCART22

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on

Sep 19, 2022

in Cornerstone Blog

Where Discovery Leads: CAR T-Cell Therapy Research

CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Evan Weber, PhD

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:

weberew [at] chop.edu

Sequencing Bone Marrow DNA, Neonates, Greening Interventions, Beckwith-Wiedemann Spectrum

Published on

Dec 10, 2021

in Cornerstone Blog

Our research news highlights a study about sequencing bone marrow DNA after CAR T-cell therapy and how it accurately predicts leukemia relapse.

Pediatric Cancer Dream Team Receives Team Science Award From AACR

Published on

Jul 8, 2021

in Cornerstone Blog

‘Dream Team’ Receives Team Science Award From AACR

The “Pediatric Cancer Dream Team”, co-led by Dr. John Maris, received the Team Science Award from the AACR.

Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

Study of Efficacy and Safety of Tisagenlecleucel in Children and Young Adults with HR B-ALL that is end-consolidation MRD Positive (AALL1721/CASSIOPEIA)

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia that remains MRD-positive after 2 cycles of chemotherapy.

Hodgkin Lymphoma (NHL) (BIANCA)

This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).